Investing
Top Active Trader Alert Stocks (FNDT, NFLX, TSPT, UBS)
Published:
Last Updated:
Active traders and day traders have many stocks to choose from this Thursday morning. We are tracking news and moves in shares of Fundtech, Ltd. (NASDAQ: FNDT), Netflix, Inc. (NASDAQ: NFLX), Transcept Pharmaceuticals (NASDAQ: TSPT), and UBS (NYSE: UBS).
Fundtech, Ltd. (NASDAQ: FNDT) is up more than 31% premarket to $23.02, relative to a 52-week range of $13.17 – $21.35. The company has received multiple competing acquisition offers.
Netflix, Inc. (NASDAQ: NFLX) is down more than 14% premarket to $179, within a 52-week range of $140.02 – $304.79. The company has lowered its subscriber outlook significantly.
Transcept Pharmaceuticals (NASDAQ: TSPT) is up nearly 70% premarket to $5.65, relative to a 52-week range of $2.58 – $11.88. The company’s new sleep aid is rumored to be nearing approval.
UBS (NYSE: UBS) is down 10.8% premarket to $11.31, relative to a 52-week range of $11.53 – $20.08. According to the company, a rogue trader managed to accumulate nearly $2 billion in losses before being caught.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
